Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 2/20 | 0.36 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.33 |
| ▸ | HTR3B | O95264 | 1/20 | 0.33 |
| ▸ | HTR3A | P46098 | 1/20 | 0.33 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.33 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | CASR | P41180 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.30 |
| ▸ | RORA | P35398 | 1/20 | 0.30 |
| ▸ | RORB | Q92753 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | UBE2N | P61088 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20183580 | 0.89 | PER2 (0.35) | TP53RORCHTR3EHTR3BHTR3A | |
| SCHEMBL20183793 | 0.88 | HSP90AA1 (0.36) | TP53MAPTRORCHTR3EHTR3B | |
| SCHEMBL20806146 | 0.88 | TP53 (0.35) | TP53MAPTRORCHTR3EHTR3B | |
| SCHEMBL20183755 | 0.88 | NPY5R (0.34) | TP53MAPTRORCHTR3EHTR3B | |
| SCHEMBL20183742 | 0.86 | ALDH1A1 (0.38) | MAPTRORCHTR3EHTR3BHTR3A | |
| SCHEMBL20183728 | 0.86 | MAPT (0.40) | TP53MAPTRORCHTR3EHTR3B | |
| SCHEMBL20183740 | 0.86 | TP53 (0.42) | TP53MAPTRORCHTR3EHTR3B | |
| SCHEMBL20183844 | 0.86 | NPY5R (0.35) | TP53MAPTRORCHTR3EHTR3B | |
| SCHEMBL20183692 | 0.85 | PDE4A (0.36) | MAPTRORCALDH1A1KDM4ENPY5R | |
| SCHEMBL20183718 | 0.84 | NPY5R (0.34) | RORCHTR3EHTR3BHTR3AHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10987349-B2 | Antitumor agent and bromodomain inhibitor | FUJIFILM CORPORATION (JP) | 2021-04-27 | — | — | US | disclosed |
| US-10987349-B2 | Antitumor agent and bromodomain inhibitor | FUJIFILM CORPORATION (JP) | 2021-04-27 | — | — | US | disclosed |
| EP-3563851-B1 | ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR | FUJIFILM CORP (JP) | 2021-04-21 | — | — | EP | disclosed |
| EP-3327004-B1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | FUJIFILM CORP (JP) | 2020-11-04 | — | — | EP | disclosed |
| EP-3327004-B1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | FUJIFILM CORP (JP) | 2020-11-04 | — | — | EP | disclosed |
| US-10696637-B2 | Nitrogen-containing heterocyclic compound | FUJIFILM CORPORATION (JP) | 2020-06-30 | — | — | US | disclosed |
| US-10696637-B2 | Nitrogen-containing heterocyclic compound | FUJIFILM CORPORATION (JP) | 2020-06-30 | — | — | US | disclosed |
| US-10633343-B2 | — | — | 2020-04-28 | — | — | US | disclosed |
| US-10633343-B2 | — | — | 2020-04-28 | — | — | US | disclosed |
| EP-3563851-A1 | ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR | FUJIFILM Corporation (JP) | 2019-11-06 | — | — | EP | disclosed |
| US-20190314360-A1 | ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR | FUJIFILM CORPORATION (JP) | 2019-10-17 | — | — | US | disclosed |
| US-20190314360-A1 | ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR | FUJIFILM CORPORATION (JP) | 2019-10-17 | — | — | US | disclosed |
| US-20190077761-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | FUJIFILM CORPORATION (JP) | 2019-03-14 | — | — | US | disclosed |
| US-20190077761-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | FUJIFILM CORPORATION (JP) | 2019-03-14 | — | — | US | disclosed |
| EP-3327004-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | Fujifilm Corporation (JP) | 2018-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10987349-B2 | Antitumor agent and bromodomain inhibitor | BRD4, BRD1, BRD3 | TP53 94/4885MAPT 3928/4885RORC 2166/4885 |
| US-10696637-B2 | Nitrogen-containing heterocyclic compound | CXCL10, CCL5, CXCR3 | TP53 1844/4885MAPT 4325/4885RORC 2610/4885 |
| US-20190314360-A1 | ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR | BRD4, BRD1, BRD3 | TP53 94/4885MAPT 3928/4885RORC 2166/4885 |
| US-20190077761-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | CXCL10, CCL5, CXCR3 | TP53 1844/4885MAPT 4325/4885RORC 2610/4885 |
| US-10633343-B2 | — | CXCL10, CCL5, CXCR3 | TP53 1821/4885MAPT 4406/4885RORC 2295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.